What is de novo metastatic breast cancer?
If you’ve never had breast cancer in the past and your first diagnosis is stage IV, you have de novo metastatic breast cancer.
- Medical Review: Rebecca Jaslow, MD
De novo metastatic breast cancer is breast cancer that has already traveled outside the breast to distant areas of the body, such as the bones or liver, by the time it is first diagnosed. This is stage IV breast cancer. If you’ve never had breast cancer in the past and your first diagnosis is stage IV, you have de novo metastatic breast cancer. While stage IV disease is not curable, it is treatable.
Having stage IV breast cancer means being in treatment for life. Unlike for earlier stages of breast cancer, the goal of treatment for metastatic disease is not to cure it, but to control the cancer for as long as possible while managing the side effects of treatment so that you can have the best quality of life possible. This can mean treatments to shrink tumors or weaken the cancer and to relieve symptoms and side effects in the most effective way.
Most people diagnosed with metastatic breast cancer have early-stage disease first. In fact, only about 3 to 6 percent of newly diagnosed breast cancers are de novo metastatic.
Learning you have de novo metastatic breast cancer as your first diagnosis can be very overwhelming. Not only is the diagnosis itself scary, but you don’t have the benefit of past experience with breast cancer treatments to have a sense of what comes next. We’re here to help you through this. Below, we explain why de novo metastatic breast cancer can happen, what treatments are available, and ways to cope emotionally as you transition from life without cancer to living long-term with it.
If you’d like to talk to someone like you about their experience, we encourage you to contact the LBBC Breast Cancer Helpline to be matched with a trained volunteer. You can also learn about other resources, including support groups and LBBC private Facebook groups, on our Finding support page.
Why de novo metastatic breast cancer occurs
There is no known biological reason that some people are diagnosed with de novo metastatic breast cancer. When a person is diagnosed de novo metastatic, there is often evidence of cancer cells in the breast that were not detected or treated before traveling outside of the breast.
Risk factors
Risk factors for de novo metastatic breast cancer are the same as risk factors for breast cancer of any stage. While some risks cannot be controlled, others can.
Risk factors that cannot be controlled:
- Being born female
- Getting older; risk increases after age 55
- Family history of breast cancer
- Inherited gene mutations, such as BRCA1 or BRCA2
- Having Ashkenazi Jewish heritage
- Previous radiation therapy to the chest
- Having dense breast tissue
- Starting menstrual periods early
- Going through menopause after age 55
- Never carrying a pregnancy
- Carrying your first pregnancy after age 30
- Exposure to diethylstilbestrol (DES, a drug used in the 1940s through the early 1970s to lower risk of miscarriage)
Risk factors that can be controlled:
- Lack of exercise
- Postmenopausal weight gain
- Drinking alcohol
- Taking certain kinds of hormone replacement therapy (not the same as anti-estrogen therapy for breast cancer) after menopause for more than 5 years
People more likely to be diagnosed with de novo metastatic breast cancer
There are certain groups of people who are more likely to be diagnosed with de novo metastatic breast cancer than others, because of factors that are often very challenging or not possible to control. These groups are:
- Women from low-income geographic areas. Research shows that women from high-poverty areas have a higher rate of being diagnosed with higher stages of breast cancer, because for these women:
- There is a lower likelihood of having a regular healthcare provider, which means getting breast cancer screenings less frequently.
- There is less access to education and to breast cancer information on prevention and early detection.
- There is less likelihood of having private health insurance. Not having health insurance can make treatment unaffordable.
- There are other barriers to getting healthcare, such as unreliable transportation and being unable to take time off of work for treatment.
- Black women. A 2018 study found that Black women were more likely than white or Hispanic women to be diagnosed with de novo metastatic breast cancer.
- Older women. In a 2018 study that used data collected by the Surveillance, Epidemiology, and End Results program (SEER), researchers found that women age 60-69 had the highest number of de novo diagnoses.
People who are not in the above groups can also be diagnosed with de novo metastatic breast cancer.
Symptoms
Whether you’ve been diagnosed with de novo metastatic breast cancer or metastatic breast cancer that is a recurrence of an early-stage breast cancer, symptoms can include:
- Severe fatigue
- Weight loss
- Nausea
- Vomiting
- Generally not feeling well
- Pain that doesn’t go away
- Loss of appetite
Because breast cancer cells can spread to any part of the body, the symptoms you experience usually show up in the area where the cancer spread. For example, back pain or joint pain can be symptoms of metastatic breast cancer to the bone, while shortness of breath and difficulty breathing can be symptoms of metastatic breast cancer to the lungs. This also means that the symptoms you have can be very different from the symptoms someone else experiences.
Bone
- Pain in back or neck
- Breaks or fractures
- Pain with numbness in arms, legs, hands, or feet
Liver
- Sudden weight loss
- Abdominal pain or swelling
- Swelling of the legs
Lungs
- Shortness of breath while doing day-to-day activities
- Stubborn, dry cough
- Coughing up blood
- Sudden chest pain
Brain
- Headache
- Dizziness
- Changed vision
- Trouble remembering
- Seizure
General
- Nausea
- Vomiting
- Fatigue
Diagnosis
De novo metastatic breast cancer is diagnosed using the same tools used to diagnose other types of breast cancer. Doctors use a mix of imaging tests, blood tests, and a biopsy to confirm cancer. Depending on the area of the body being tested, you may need:
- A checkup with your primary care physician, who may refer you to a specialist if they are concerned about your symptoms
- Imaging tests to look at parts of your body for signs of cancer, such as MRIs, CT scans, bone scans, x-rays, or PET scans
- Blood tests, which look at how well the liver and kidneys are working, and complete blood counts, which look at how many red and white blood cells are in your blood
- A biopsy, a procedure to collect tissue samples to test for cancer cells
To learn more, visit our page on tests that can help diagnose metastatic breast cancer.
Treatment options
Your treatment for de novo metastatic breast cancer will be based on several factors, such as where in the body the cancer cells have spread and specific characteristics of the cancer cells.
Breast cancer cells can have different features that determine the kinds of treatments your care team may recommend. The cells can be:
- Hormone receptor-positive, which means that the cancer cells grow in response to the hormones estrogen or progesterone, and can be treated with hormonal therapy
- HER2-positive, which means that the cancer cells have higher-than-normal levels of a protein called HER2, causing the cells to grow quickly, and can be treated with HER2-targeted therapies
- Triple-negative, which means the cancer is not growing because of hormones or the HER2 protein, so different treatments, such as immunotherapy, chemotherapy, and targeted therapy, may be used
For people who test positive for a BRCA1 or BRCA2 mutation and are diagnosed with hormone receptor-positive, HER2-negative breast cancer, or triple-negative breast cancer, PARP inhibitors may be a treatment option. These targeted therapies stop an enzyme in the body known as poly (ADP-ribose) polymerase, or PARP, from repairing cancer cell DNA. Cancer cells in people with BRCA mutations already have a hard time repairing their own DNA. PARP inhibitors make it even harder, and can cause the cancer cells to die.
The most common places for breast cancer to spread include the bones, liver, lungs, and brain.
Because treatment options are based on the characteristics of the breast cancer and the location of spread, your plan will be highly individual to your situation. Other people living with metastatic breast cancer may have different treatment plans. And compared with early-stage breast cancer treatments, metastatic breast cancer treatments may not seem as aggressive. This is because early-stage treatment happens over a shorter period of time, and the goal is to get rid of all the cancer. Treatment for metastatic breast cancer works to control the cancer for as long as possible, while helping you live with as few treatment side effects as possible.
Your treatment plan may change over time as the cancer adapts and builds resistance to medicines. Usually, a treatment is used until the cancer grows or travels to a new part of the body. Treatments may also change if side effects are interfering with your daily activities and quality of life. Sometimes, a treatment is used for many months or years, and other times, a treatment might need to change after a shorter period. Always let your care team know how you’re feeling and any side effects you’re experiencing. If it looks like a new treatment may be needed, you and your care team will talk about options to try.
Treatment options for metastatic breast cancer include:
- Hormonal therapy. Hormonal therapies are medicines that block or lower estrogen that helps hormone receptor-positive breast cancer to grow. These medicines are only given to people diagnosed with hormone receptor-positive breast cancer.
- Targeted therapy. Targeted therapies are medicines that target certain characteristics or behaviors of cancer cells to stop or slow the growth of the cancer. Targeted therapies can also target processes in the body that help cancer cells grow. These medicines are only offered to people with hormone receptor-positive, HER2-positive breast cancer, or both.
- Chemotherapy. Chemotherapy is a type of medicine that destroys or slows the growth of rapidly dividing cells throughout the body, including cancer cells.
- Immunotherapy. Immunotherapy uses the body’s own defense system to recognize and destroy cancer cells.
- Surgery. While most people with metastatic breast cancer do not need surgery, in some cases it can be used to ease symptoms such as pain, fractures, or bleeding.
- Radiation therapy. Radiation can be used to relieve bone pain, prevent or ease symptoms of brain or lung metastases, and treat issues of the spine caused by bone metastases.
- Palliative care. Palliative care focuses on helping people with serious illness to manage side effects and to feel more physically and emotionally supported.
Learn more about treatment options for metastatic breast cancer.
How to cope
Learning you have de novo metastatic breast cancer when you’ve never had breast cancer before can be a shock to the system. Anxiety, sadness, anger, and numbness are all normal feelings to have in a situation that may feel anything but normal. There’s no right way to feel. Feelings may change from day to day. And while metastatic breast cancer is not considered curable, it is treatable — and it is still possible to continue living a life that makes you feel fulfilled.
We know that balancing overwhelming emotions with the practical needs of treatment planning can sometimes feel impossible. But you don’t have to do this alone or without help! There are many ways to feel more supported and connected. We’re here for you with information about:
- Talking with close family and friends
- Trying complementary therapies
- Learning strategies for coping with breast cancer
- Finding support
- Joining a breast cancer support group
- Maintaining intimacy and sexuality
- Getting active
It’s OK if it takes you a while to find something that helps you feel calm and centered, and if you need to try different things before you decide what works for you — this is your experience, and your life. You are the only person you need to satisfy when it comes to living with metastatic breast cancer.
We encourage you to call our Breast Cancer Helpline to be matched with a trained volunteer who is also living with metastatic breast cancer. Our volunteers are available to talk with you and offer guidance, emotional support, and hope.
Related news
- Imlunestrant proves effective against hormone receptor-positive, HER2-negative advanced breast cancer | SABCS 2024
- A new era in dosing: Dose optimization | SABCS 2024
- Living Beyond Breast Cancer awarded two grants raising $1,985,000 over 5 years
- Enfortumab vedotin shows anti-tumor activity but does not meet trial goals | ASCO 2024
Free downloads
Stay connected
Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.
- 3-dimensional radiation therapy
- 4-hydroxytamoxifen
- ablation
- abnormal
- Abraxane
- absolute risk
- AC regimen
- AC-T regimen
- AC-T-T regimen
- AC-Taxol regimen
- AC-TH regimen
- accelerated partial-breast irradiation
- action study
- acupoint
- acupressure
- acupuncture
- acupuncture needle
- acupuncture point
- acupuncture point injection
- acupuncturist
- acustimulation
- acute
- acute pain
- adenocarcinoma
- adenopathy
- adenosis
- adjunct agent
- adjunct therapy
- adjunctive therapy
- adjuvant therapy
- advance directive
- advanced practice nurse
- adverse effect
- aerobic exercise
- agent study
- aggravating factor
- aggressive
- AJCC staging system
- Alkeran
- alkylating agent
- Allegra
- allopathic medicine
- alopecia
- amifostine
- aminoglutethimide
- amitriptyline
- anabolic steroid
- analgesic
- anaplastic
- anastrozole
- ancillary test
- anemia
- anesthesia
- anesthesiologist
- angiogenesis
- angiogenesis inhibitor
- antagonist
- anthracycline
- anti-anxiety medicine
- anti-idiotype vaccine
- anti-inflammatory
- antibody-dependent cellular cytotoxicity
- antibody therapy
- anticachexia
- anticancer antibiotic
- anticancer therapy
- anticonvulsant
- antidepressant
- antiemetic
- antiestrogen
- antifolate
- antigen-presenting cell vaccine
- antihormone therapy
- antimetabolite
- antimitotic agent
- antineoplastic
- antitumor
- anxiety
- anxiolytic
- Anzemet
- APN
- apocrine gland
- apoptosis
- aprepitant
- areola
- Aromasin
- aromatase inhibitor
- aromatherapy
- arthralgia
- ascites
- aspirate
- aspiration
- assay
- asthenia
- asymptomatic
- atypia
- atypical ductal hyperplasia
- atypical hyperplasia
- atypical lobular hyperplasia
- avoidance
- axillary lymph node
- axillary lymph node dissection
- BAK gel
- balloon catheter radiation
- baseline
- behavior modification
- best practice
- BI-RADS
- Biafine cream
- bias
- bilateral
- bilateral breast cancer
- bilateral prophylactic mastectomy
- bilateral salpingo-oophorectomy
- biofeedback
- biologic
- biopsy
- biopsy specimen
- biotherapy
- bisphosphonate
- bisphosphonate-associated osteonecrosis
- blinded study
- blood-brain barrier
- blood-brain barrier disruption
- blood cell count
- blood chemistry study
- board certified oncology pharmacy specialist
- body image
- body mass index
- bolus dose
- bone density
- bone metastasis
- bone mineral density scan
- bone scan
- bone-seeking radioisotope
- brachytherapy
- brain metastasis
- BRCA1
- BRCA2
- BRCAPro
- breast carcinoma in situ
- breast-conserving surgery
- breast density
- breast duct
- breast duct endoscopy
- breast lobe
- breast lobule
- breast reconstruction
- breast self-exam
- Brief Pain Inventory
- cachexia
- CAF regimen
- calcification
- cancer vaccine
- candidiasis
- capecitabine
- carboplatin
- carcinogen
- carcinoma
- carcinoma in situ
- carcinomatous meningitis
- carcinosis
- carcinostatic
- cardiotoxicity
- caregiver
- carmustine
- case-control study
- case report
- case series
- CAT scan
- CBC
- cell
- cell-cycle regulation
- cell proliferation
- central nervous system
- central nervous system metastasis
- central nervous system prophylaxis
- central venous access catheter
- cetuximab
- cevimeline
- chaplain
- charged-particle radiation therapy
- chemoembolization
- chemoimmunotherapy
- chemoprevention
- chemoprevention study
- chemoprotective
- chemoradiation
- chemosensitivity
- chemosensitivity assay
- chemosensitizer
- chemotherapeutic agent
- chemotherapy
- chest wall
- chest X-ray
- Chinese meridian theory
- chronic
- chronic pain
- cisplatin
- Claus model
- clergy
- clinical
- clinical breast exam
- clinical practice guidelines
- clinical researcher
- clinical resistance
- clinical series
- clinical stage
- clinical staging
- clinical study
- clinical trial
- clinician
- clodronate
- CMF regimen
- cognition
- cognitive behavior therapy
- cognitive therapy
- cohort
- cohort study
- coinsurance
- combination chemotherapy
- comedo carcinoma
- comfort care
- Coming Out
- Community Advisory Board
- comorbidity
- compassionate use trial
- complementary and alternative medicine
- complementary medicine
- complete metastasectomy
- complete remission
- complete response
- complex decongestive therapy
- compliance
- complication
- compression garment
- computed tomography scan
- concomitant
- concurrent therapy
- condition
- consolidation therapy
- constitutional acupuncture
- continuum of care
- contract research organization
- contraindication
- contralateral
- contrast material
- control group
- controlled clinical trial
- controlled study
- conventional medicine
- conventional therapy
- copayments
- cope
- coping skills
- core biopsy
- core needle biopsy
- corticosteroid
- counseling
- COX inhibitor
- cryoablation
- cryopreservation
- cryosurgery
- CT scan
- cultural competency
- cumulative dose
- cumulative exposure
- cure
- cutaneous
- cutaneous breast cancer
- cyclophosphamide
- cyclosporine
- CYP2D6 inhibitor
- cystosarcoma phyllodes
- cytopenia
- cytotoxic
- cytotoxic chemotherapy
- Cytoxan
- Data and Safety Monitoring Board
- DCIS
- de novo
- debulking
- deductible
- definitive surgery
- definitive treatment
- dehydration
- denosumab
- depression
- diagnosis
- diagnostic mammogram
- diagnostic procedure
- diagnostic technique
- diagnostic trial
- diameter
- diarrhea
- diaziquone
- DIEP flap
- dietary counseling
- dietary supplement
- dietitian
- differentiation
- diffuse
- digital mammography
- diphenhydramine
- discharge
- disease progression
- disease-specific survival rate
- distant cancer
- distant metastasis
- Distant recurrence
- distress
- DNR order
- docetaxel
- dolasetron
- dose
- dose-dense chemotherapy
- dose-dependent
- dose-limiting
- dose-rate
- double-blinded
- doxorubicin
- drain
- dronabinol
- droperidol
- drug interaction
- drug resistance
- drug therapy
- drug tolerance
- duct
- ductal carcinoma
- ductal carcinoma in situ
- ductal lavage
- duloxetine
- durable power of attorney
- dysfunction
- dysgeusia
- dyspepsia
- dyspnea
- early menopause
- early-stage breast cancer
- edema
- EEG biofeedback
- efficacy
- Eklund displacement views
- electroacupuncture
- electron beam
- eligibility criteria
- Ellence
- emesis
- emetic
- endocrine
- endocrine therapy
- endpoint
- energy healing
- enteral nutrition
- epidemiology
- epirubicin
- ER+
- ER-
- ER
- ER-PR-HER2/neu-
- eribulin mesylate
- erythema
- estradiol
- estrogen
- estrogen blocker
- estrogen receptor
- estrogen receptor-negative
- estrogen receptor-positive
- estrogen receptor test
- estrogen replacement therapy
- etanidazole
- etidronate
- everolimus
- Evista
- excision
- excisional biopsy
- exemestane
- expanded access trial
- experimental
- extranodal
- false-negative test result
- false-positive test result
- familial cancer
- family medical history
- Faslodex
- fast-neutron beam radiation
- fatigue
- FDA
- febrile neutropenia
- FEC regimen
- Femara
- fertility
- fexofenadine
- fibroadenoma
- fibrocystic breast changes
- fiducial marker
- film mammography
- fine-needle aspiration biopsy
- first-degree relative
- first-line therapy
- five-year survival rate
- fluorouracil
- fluoxetine
- FNA biopsy
- focal
- Food and Drug Administration
- Fosamax
- fractionation
- fulvestrant
- functional magnetic resonance imaging
- gadolinium
- Gail model
- gallium scan
- gamma irradiation
- Gamma Knife therapy
- gamma ray
- Gelclair
- gemcitabine
- gene
- gene expression profile
- gene therapy
- general anesthesia
- generalized anxiety disorder
- generic
- genetic
- genetic counseling
- genetic marker
- genetic marker of susceptibility
- genetic predisposition
- genetic profile
- genetic susceptibility
- genetic testing
- genetic testing
- genetics
- genome
- genome-wide association study
- genomic profile
- genomic test
- genomics
- gland
- Good Clinical Practice
- goserelin
- grade
- grading
- granisetron
- gross description
- Halaven
- hazard ratio
- healing touch
- Health Insurance Portability and Accountability Act
- healthcare provider
- healthcare proxy
- healthy control
- helical computed tomography
- HER2/neu
- Herceptin
- hereditary
- hereditary mutation
- heteronormative
- high-dose chemotherapy
- high-dose radiation
- high-energy proton therapy
- high grade
- high-risk cancer
- HIPPA
- histologic examination
- histology
- historic cohort study
- historical control subject
- homeopathic medicine
- hormonal therapy
- hormone
- hormone receptor
- hormone receptor test
- hormone replacement therapy
- hormone responsive
- hormone therapy
- hospice
- hot flash
- human epidermal growth factor receptor 2
- human participant protection regulations
- hydroxydaunorubicin
- hyperalimentation
- hypercalcemia
- hyperfractionated radiation therapy
- hyperfractionation
- hyperplasia
- hypersensitivity
- hypofractionated radiation therapy
- hypofractionation
- hypoxia
- ibandronate
- ibuprofen
- idiopathic
- image-guided radiation therapy
- imaging
- imaging procedure
- immune adjuvant
- immune function
- immune response
- immune system
- immune system tolerance
- immunization
- immunoassay
- immunocompromised
- immunodeficiency
- immunohistochemistry
- immunology
- immunomodulation
- immunosuppression
- immunotherapy
- implant
- implant displacement views
- implant radiation therapy
- implantable pump
- in network
- in situ
- incidence
- incision
- incisional biopsy
- indication
- indolent
- induction therapy
- infection
- infertile
- infertility
- infiltrating breast cancer
- infiltrating ductal carcinoma
- inflammation
- inflammatory breast cancer
- informed consent
- infusion
- ingestion
- inherited
- iniparib
- injection
- inoperable
- insomnia
- Institutional Review Board
- intensification therapy
- intensity-modulated radiation therapy
- interfering thought
- internal mammary lymph nodes
- internal radiation therapy
- International Unit
- internist
- interstitial radiation therapy
- intervention
- intervention group
- intra-arterial
- intracarotid infusion
- intradermal
- intraductal breast papilloma
- intraductal carcinoma
- intrahepatic
- intrahepatic infusion
- intramuscular
- intramuscular injection
- intraoperative radiation therapy
- intraoperative ultrasound
- intratumoral
- intravasation
- intravenous
- intravenous infusion
- intravenous injection
- intrusive thought
- intrusive thoughts
- invasive breast cancer
- invasive cancer
- invasive procedure
- investigational
- investigator
- ionizing radiation
- ipsilateral
- IRB
- irradiated
- irradiation
- irreversible toxicity
- ixabepilone
- joint pain
- Karnofsky Performance Status
- laboratory test
- lapatinib
- laser
- laser surgery
- laser therapy
- lassitude
- late effects
- late-stage cancer
- latent
- laxative
- LEEP
- legal aid organization
- lesion
- lethargy
- letrozole
- leukopenia
- levels of evidence
- Lexapro
- libido
- lidocaine
- ligation
- linac
- linear accelerator
- lipoma
- lisofylline
- liver metastasis
- liver scan
- living will
- lobaplatin
- lobe
- lobectomy
- lobular carcinoma
- lobular carcinoma in situ
- lobule
- local anesthesia
- local cancer
- local therapy
- localization
- localized
- locally advanced cancer
- locally recurrent cancer
- lomustine
- loop electrosurgical excision procedure
- loop excision
- lorazepam
- low grade
- lubricant
- lumbar puncture
- lumpectomy
- lung metastasis
- luteinizing hormone-releasing hormone agonist
- lymph
- lymph gland
- lymph node
- lymph node dissection
- lymph node drainage
- lymph node mapping
- lymph vessel
- lymphadenectomy
- lymphadenopathy
- lymphangiogram
- lymphangiography
- lymphatic basin
- lymphatic fluid
- lymphatic mapping
- lymphatic system
- lymphatic vessel
- lymphedema
- lymphography
- lymphoscintigraphy
- Lyrica
- lytic lesion
- macrocalcification
- magnetic resonance imaging
- magnetic resonance perfusion imaging
- magnetic resonance spectroscopic imaging
- mainstream medicine
- maintenance therapy
- male breast cancer
- malignancy
- malignant
- malignant pleural effusion
- malnutrition
- mammary
- mammary dysplasia
- mammary gland
- mammogram
- mammography
- MammoSite
- Mammotome
- mantle field
- MAO inhibitor
- margin
- marker
- mass
- massage therapy
- mastectomy
- mastitis
- maternal
- maximum tolerated dose
- mean survival time
- measurable disease
- medial supraclavicular lymph node
- median
- median survival time
- Medicaid
- medical castration
- medical device
- medical nutrition therapy
- medical oncologist
- Medicare
- medicine
- medullary breast carcinoma
- mega-voltage linear accelerator
- megestrol
- melphalan
- meningeal metastasis
- menopause
- menorrhagia
- menstrual cycle
- menstrual period
- menstruation
- mental health
- mental health counselor
- meridian
- mesna
- meta-analysis
- metallic
- metastasectomy
- metastasis
- metastasize
- metastatic
- methotrexate
- metoclopramide
- metronomic therapy
- microcalcification
- micrometastasis
- microscopic
- milk duct
- mind/body exercise
- mindfulness relaxation
- Miraluma test
- mitigate
- modified radical mastectomy
- molecular marker
- molecular medicine
- molecular risk assessment
- molecularly targeted therapy
- monoamine oxidase inhibitor
- monoclonal antibody
- morbidity
- mortality
- MRI
- MRSI
- MTD
- mTOR
- mucositis
- multicenter study
- multicentric breast cancer
- multidisciplinary
- multidisciplinary opinion
- multidrug resistance
- multidrug resistance inhibition
- multifocal breast cancer
- music therapy
- mutation
- mutation carrier
- myalgia
- myelosuppression
- nanoparticle paclitaxel
- narcotic
- National Cancer Institute
- National Center for Complementary and Alternative Medicine
- National Institutes of Health
- natural history study
- naturopathy
- nausea
- NCCAM
- NCI
- NCI clinical trials cooperative group
- needle biopsy
- needle localization
- needle-localized biopsy
- negative axillary lymph node
- negative test result
- neoadjuvant therapy
- neoplasm
- nerve
- nerve block
- neurocognitive
- neurologic
- neuropathy
- neurotoxicity
- neurotoxin
- neutropenia
- NIH
- nipple
- nipple discharge
- nitrosourea
- NMRI
- node-negative
- node-positive
- nodule
- nonblinded
- nonconsecutive case series
- noninvasive
- nonmalignant
- nonmetastatic
- nonprescription
- nonrandomized clinical trial
- nonsteroidal anti-inflammatory drug
- nonsteroidal aromatase inhibitor
- nontoxic
- normal range
- normative
- NP
- NPO
- NSAID
- nuclear grade
- nuclear magnetic resonance imaging
- nuclear medicine scan
- nurse
- nurse practitioner
- nutrition
- nutrition therapy
- nutritional counseling
- nutritional status
- nutritional supplement
- nutritionist
- obese
- objective improvement
- objective response
- observation
- observational study
- obstruction
- off-label
- olaparib
- oncologist
- oncology
- oncology nurse
- oncology pharmacy specialist
- oncolysis
- ondansetron
- onset of action
- oophorectomy
- open biopsy
- open label study
- open resection
- operable
- opiate
- opioid
- opportunistic infection
- oral
- organ
- orthodox medicine
- osteolytic
- osteonecrosis of the jaw
- osteopenia
- osteoporosis
- OTC
- out of network
- outcome
- outpatient
- ovarian
- ovarian ablation
- ovarian cancer
- ovarian suppression
- ovary
- over-the-counter
- overall survival rate
- overdose
- overexpress
- overweight
- ovulation
- PA
- paclitaxel
- paclitaxel albumin-stabilized nanoparticle formulation
- paclitaxel-loaded polymeric micelle
- Paget disease of the nipple
- pain threshold
- palliation
- palliative care
- palliative therapy
- palmar-plantar erythrodysesthesia
- palonosetron hydrochloride
- palpable disease
- palpation
- palpitation
- pamidronate
- panic
- papillary tumor
- Paraplatin
- parenteral nutrition
- paroxetine hydrochloride
- PARP
- PARP inhibitor
- partial-breast irradiation
- partial mastectomy
- partial oophorectomy
- partial remission or partial response
- pastoral counselor
- paternal
- pathologic fracture
- pathological stage
- pathological staging
- pathologist
- pathology report
- patient advocate
- Paxil
- peau d'orange
- pedigree
- peer-review process
- peer-reviewed scientific journal
- perfusion magnetic resonance imaging
- perimenopausal
- periodic neutropenia
- perioperative
- peripheral neuropathy
- peripheral venous catheter
- personal health record
- personal medical history
- personalized medicine
- Pertuzumab
- PET scan
- pharmacist
- phase I/II trial
- phase I trial
- phase II/III trial
- phase II trial
- phase III trial
- phase IV trial
- phlebotomy
- photon beam radiation therapy
- phyllodes tumor
- physical examination
- physical therapist
- physical therapy
- physician
- physician assistant
- physiologic
- PI3 kinase inhibitor
- pilocarpine
- pilot study
- placebo
- placebo-controlled
- plastic surgeon
- plastic surgery
- population study
- positive axillary lymph node
- positive test result
- positron emission tomography scan
- post-traumatic stress disorder
- postmenopausal
- postoperative
- postremission therapy
- potentiation
- power of attorney
- PR
- PR+
- PR-
- practitioner
- preauthorization
- precancerous
- preclinical study
- predictive factor
- pregabalin
- premalignant
- premature menopause
- premenopausal
- premium
- prescription
- prevention
- preventive
- preventive mastectomy
- primary care
- primary care doctor
- primary endpoint
- primary therapy
- primary treatment
- primary tumor
- Principal investigator
- prochlorperazine
- progesterone
- progesterone receptor
- progesterone receptor-negative
- progesterone receptor-positive
- progesterone receptor test
- progestin
- prognosis
- prognostic factor
- progression
- progression-free survival
- progressive disease
- Prolia
- proliferative index
- promegapoietin
- prophylactic
- prophylactic mastectomy
- prophylactic oophorectomy
- prophylactic surgery
- prophylaxis
- prospective
- prospective cohort study
- prosthesis
- protective factor
- protein
- protein-bound paclitaxel
- protein expression
- protein expression profile
- protocol
- proton
- proton magnetic resonance spectroscopic imaging
- pruritus
- psychiatrist
- psychological
- psychologist
- psychosocial
- psychotherapy
- PTSD
- pump
- punch biopsy
- qi
- qigong
- quadrantectomy
- quality assurance
- quality of life
- radiation
- radiation brachytherapy
- radiation dermatitis
- radiation fibrosis
- radiation necrosis
- radiation nurse
- radiation oncologist
- radiation physicist
- radiation surgery
- radiation therapist
- radiation therapy
- radical lymph node dissection
- radical mastectomy
- radioactive
- radioactive drug
- radioactive seed
- radioisotope
- radiologic exam
- radiologist
- radiology
- radionuclide
- radionuclide scanning
- radiopharmaceutical
- radiosensitization
- radiosensitizer
- radiosurgery
- radiotherapy
- raloxifene
- raloxifene hydrochloride
- randomization
- randomized clinical trial
- receptor
- RECIST
- reconstructive surgeon
- reconstructive surgery
- recreational therapy
- recurrence
- recurrent cancer
- referral
- reflexology
- refractory
- refractory cancer
- regimen
- regional
- regional anesthesia
- regional cancer
- regional chemotherapy
- regional lymph node
- regional lymph node dissection
- registered dietician
- regression
- rehabilitation
- rehabilitation specialist
- relapse
- relative survival rate
- relaxation technique
- remission
- remission induction therapy
- remote brachytherapy
- research nurse
- research study
- resectable
- resected
- resection
- residual disease
- resistant cancer
- resorption
- respite care
- response rate
- retrospective cohort study
- retrospective study
- risk factor
- Rubex
- salpingo-oophorectomy
- salvage therapy
- samarium 153
- sargramostim
- scalpel
- scan
- scanner
- scintigraphy
- scintimammography
- sclerosing adenosis
- screening
- screening mammogram
- second-line therapy